Development of a NanoBRET Assay Platform to Detect Intracellular Ligands for the Chemokine Receptors CCR6 and CXCR1

• Published in: ChemMedChem 2024-10, Vol.19 (20), p.e202400284-n/a
• Main Authors: Huber, Max E., Wurnig, Silas L., Moumbock, Aurélien F. A., Toy, Lara, Kostenis, Evi, Alonso Bartolomé, Ana, Szpakowska, Martyna, Chevigné, Andy, Günther, Stefan, Hansen, Finn K., Schiedel, Matthias
• Format: Article
• Language: English
• Subjects: Allosteric modulators; Allosteric properties; Assaying; Binding sites; CC chemokine receptors; Chemokine receptors; Chemokines; Clinical trials; Coupled modes; CXCR2 protein; Dose-Response Relationship, Drug; Drug discovery; Fluorescence; Fluorescent Dyes - chemical synthesis; Fluorescent Dyes - chemistry; Fluorescent Dyes - pharmacology; G protein-coupled receptors; GPCRs; Health services; Humans; Immunomodulation; Intracellular; Ligands; Lung diseases; Medicinal Chemistry; Molecular Structure; NanoBRET; Receptors, CCR6 - antagonists & inhibitors; Receptors, CCR6 - metabolism; Receptors, Interleukin-8A - antagonists & inhibitors; Receptors, Interleukin-8A - metabolism; Structure-Activity Relationship; Target detection; Therapeutic targets; Ulcerative colitis
• ISSN: 1860-7179; 1860-7187; 1860-7187
• DOI: 10.1002/cmdc.202400284

A conserved intracellular allosteric binding site (IABS) was recently identified at several G protein‐coupled receptors (GPCRs). This target site allows the binding of allosteric modulators and enables a new mode of GPCR inhibition. Herein, we report the development of a NanoBRET‐based assay platform based on the fluorescent ligand LT221 (5), to detect intracellular binding to CCR6 and CXCR1, two chemokine receptors that have been pursued as promising drug targets in inflammation and immuno‐oncology. Our assay platform enables cell‐free as well as cellular NanoBRET‐based binding studies in a nonisotopic and straightforward manner. By combining this screening platform with a previously reported CXCR2 assay, we investigated CXCR1/CXCR2/CCR6 selectivity profiles for both known and novel squaramide analogues derived from navarixin, a known intracellular CXCR1/CXCR2 antagonist and phase II clinical candidate for the treatment of pulmonary diseases. By means of these studies we identified compound 10, a previously reported tert‐butyl analogue of navarixin, as a low nanomolar intracellular CCR6 antagonist. Further, our assay platform clearly indicated intracellular binding of the CCR6 antagonist PF‐07054894, currently evaluated in phase I clinical trials for the treatment of ulcerative colitis, thereby providing profound evidence for the existence and the pharmacological relevance of a druggable IABS at CCR6. Our newly developed NanoBRET assay platform allows the detection of intracellular ligand binding to CCR6 and CXCR1, enables equilibrium as well as kinetic binding studies in a cell‐free and cellular environment, provides further evidence for the existence of a druggable IABS at CCR6 and CXCR1, and allows mapping of CCR6 and CXCR1 ligands to distinct binding sites of the receptor.